HCC827 GR5Homo sapiens (Human)Cancer cell line

Also known as: HCC827GR5, HCC-827-GR5, HCC827-GR5

AI Summary

No AI-generated summary available for this cell line.

Basic Information

Database IDCVCL_V622
SpeciesHomo sapiens (Human)
Tissue SourceLung[UBERON:UBERON_0002048]

Donor Information

Age39
Age CategoryAdult
SexFemale
Racecaucasian

Disease Information

DiseaseLung adenocarcinoma
LineageLung
SubtypeLung Adenocarcinoma
OncoTree CodeLUAD

DepMap Information

Source TypeAcademic lab
Source IDACH-000029_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Val218del (c.646_648GTG[2]) (c.652_654delGTG)Homozygous-PubMed=31541927
MutationSimpleEGFRp.Glu746_Ala750del (c.2236_2250del15)Unspecified-PubMed=16105816
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.

Nakagawa K.

Mol. Cancer Ther. 9:2785-2792(2010).

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Johnson B.E., Cantley L.C., Janne P.A.

Science 316:1039-1043(2007).